Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aurinia Pharmaceuticals

Explore full profile

Late-stage biopharma developing therapies for serious diseases, including voclosporin for lupus nephritis, proteinuric diseases, and dry eye syndrome

Edmonton, CanadaFounded 1993Biotech & Life Sciences
Valuation $2.17B Market cap · 2026
Revenue $326M Latest reported FY
EBITDA $140M Latest reported FY

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat autoimmune diseases. The company primarily serves patients suffering from conditions such as lupus nephritis, a severe inflammation of the kidneys caused by systemic lupus erythematosus. Operating in the pharmaceutical market, Aurinia's business model revolves around research and development (R&D), clinical trials, and the subsequent commercialization of approved therapies. Revenue is generated through the sale of its flagship product, LUPKYNIS, which is designed to improve kidney function in lupus nephritis patients. The company also engages in strategic partnerships and licensing agreements to expand its market reach and enhance its product pipeline.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1993
Headquarters
Edmonton, Canada
Listing
IPO 1996
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later9 investors entered at this stage

  • Difference Capital
  • Lumira Ventures
  • Great Point Partners
  • venBio Partners
  • NEA
  • Apple Tree Partners
  • Redmile Group
  • RA Capital Management
  • Tang Capital

Talent

Book a demo to see the people
Team profiled 23 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 12 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.5%
🇨🇦 Canada5.5%
2 countries shown
Web traffic by country
12K monthly visits
across markets
🇺🇸 United States35%
🇨🇦 Canada30%
🏳️ Korea2.5%
🏳️ Republic of0%
Top 4 markets shown

Patents

Estimated portfolio value
$159M

78 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aurinia Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aurinia Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles